Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia

References

• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333
   PubMed Web of Science ®Google Scholar
• Fenaux P, Preudhomme C, Lai J L, Quiquandon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre M H, Bauters F. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992; 6: 246–250
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Kopecky K J, Meshinchi S, Appelbaum F R, Slovak M L, Willman C L, Radich J P. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589–3595
   PubMed Web of Science ®Google Scholar
• Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986; 6: 1379–1385
   PubMed Web of Science ®Google Scholar
• Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342–348
   PubMed Web of Science ®Google Scholar
• Ko L J, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054–1072
   PubMed Web of Science ®Google Scholar
• Chin K V, Ueda K, Pastan I, Gottesman M M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459–462
   PubMed Web of Science ®Google Scholar
• Eischen C M, Weber J D, Roussel M F, Sherr C J, Cleveland J L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658–2669
   PubMed Web of Science ®Google Scholar
• Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102–109
   PubMed Web of Science ®Google Scholar
• Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 1998; 95: 5–8
   PubMed Web of Science ®Google Scholar
• Tidefelt U, Elmhorn-Rosenborg A, Paul C, Hao X Y, Mannervik B, Eriksson L C. Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res 1992; 52: 3281–3285
   PubMed Web of Science ®Google Scholar
• Sundman-Engberg B, Tidefelt U, Gruber A, Paul C. Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs. in vivo. Leuk Res 1993; 17: 347–352
   PubMed Web of Science ®Google Scholar
• Rhedin A S, Tidefelt U, Jonsson K, Lundin A, Paul C. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells. Leuk Res 1993; 17: 271–276
   PubMed Web of Science ®Google Scholar
• Andreotti P E, Cree I A, Kurbacher C M, Hartmann D M, Linder D, Harel G, Gleiberman I, Caruso P A, Ricks S H, Untch M, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995; 55: 5276–5282
   PubMed Web of Science ®Google Scholar
• Cree I A, Neale M H, Myatt N E, de Takats P G, Hall P, Grant J, Kurbacher C M, Reinhold U, Neuber K, MacKie R M, Chana J, Weaver P C, Khoury G G, Sartori C, Andreotti P E. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 1999; 10: 437–444
   PubMed Web of Science ®Google Scholar
• Kangas L, Gronroos M, Nieminen A L. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 1984; 62: 338–343
   PubMedGoogle Scholar
• Pinzani P, Carotti S, Gerli A, Pazzagli M, Mazzei T, Mini E. Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay. Anticancer Drugs 1997; 8: 767–777
   PubMed Web of Science ®Google Scholar
• Tidefelt U, Prenkert M, Paul C. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells. Cancer Chemother Pharmacol 1996; 38: 476–480
   PubMed Web of Science ®Google Scholar
• Squatrito R C, Connor J P, Buller R E. Comparison of a novel redox dye cell growth assay to the ATP bioluminescence assay. Gynecol Oncol 1995; 58: 101–105
   PubMed Web of Science ®Google Scholar
• Soenen V, Preudhomme C, Roumier C, Daudignon A, Lai J L, Fenaux P. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91: 1008–1015
   PubMed Web of Science ®Google Scholar
• Yin B, Kogan S C, Dickins R A, Lowe S W, Largaespada D A. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol 2006; 34: 631–641
   PubMed Web of Science ®Google Scholar
• Nakai H, Misawa S, Toguchida J, Yandell D W, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 1992; 52: 6588–6593
   PubMed Web of Science ®Google Scholar
• Harris C C, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Kowalczyk J, Sandberg A A. A possible subgroup of ALL with 9p. Cancer Genet Cytogenet 1983; 9: 383–385
   PubMed Web of Science ®Google Scholar
• Diaz M O, Rubin C M, Harden A, Ziemin S, Larson R A, Le Beau M M, Rowley J D. Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 1990; 322: 77–82
   PubMed Web of Science ®Google Scholar
• Siebert R, Willers C P, Schramm A, Fossa A, Dresen I M, Uppenkamp M, Nowrousian M R, Seeber S, Opalka B. Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol 1995; 91: 350–354
   PubMed Web of Science ®Google Scholar
• Momand J, Zambetti G P, Olson D C, George D, Levine A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237–1245
   PubMed Web of Science ®Google Scholar
• Bates S, Phillips A C, Clark P A, Stott F, Peters G, Ludwig R L, Vousden K H. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124–125
   PubMed Web of Science ®Google Scholar
• Ito A, Lai C H, Zhao X, Saito S, Hamilton M H, Appella E, Yao T P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20: 1331–1340
   PubMed Web of Science ®Google Scholar
• Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G, Wiman K G, Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br J Haematol 2006; 132: 230–236
   PubMed Web of Science ®Google Scholar
• Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman K G, Paul C, Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br J Haematol 2004; 127: 285–291
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, Samudio I J, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev L T, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150–3159
   PubMed Web of Science ®Google Scholar